Helios Cardio — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Helios Cardio is a private, clinical-stage biotech targeting major unmet needs in cardiovascular disease through a regenerative medicine platform. Its lead product, CardiaMend™, is an FDA-cleared device for pericardial and epicardial repair, providing an initial commercial foothold. The company's broader pipeline leverages its proprietary f-EBM scaffold, investigating it both as a monotherapy and in combination with cells or drugs for indications like heart failure and postoperative complications, led by a team with a proven track record in regenerative medicine.

Cardiovascular DiseaseHeart FailureCardiac Surgery

Technology Platform

Fetal Engineered Biologic Matrix (f-EBM): A biologic tissue scaffold derived from fetal dermis, engineered to provide mechanical strength and a cell-friendly microenvironment to support cardiac tissue repair and regeneration, designed for use as a monotherapy or in combination with cells/drugs.

Opportunities

The massive and growing heart failure market, estimated at over $30 billion in annual U.S.

costs, represents a primary opportunity for a disease-modifying therapy.

Additionally, preventing costly complications like postoperative atrial fibrillation addresses a clear need in cardiac surgery, offering potential for improved patient outcomes and reduced hospital expenditures.

Risk Factors

Key risks include the high clinical and regulatory uncertainty of advancing novel regenerative combination products through development, and the commercialization challenge of achieving surgeon adoption for new biologic scaffolds in a conservative surgical landscape.

The company's platform must also prove superior to competing regenerative approaches.

Competitive Landscape

Helios Cardio competes in the cardiac surgery biologics space with companies offering pericardial patches (e.g., Baxter's Peri-Strips, LeMaitre's CardioCel). For regenerative applications, it faces broader competition from companies developing cell therapies, gene therapies, and other device-based solutions for heart failure from firms like BioVentrix, Celyad (formerly), and numerous large medtech and biopharma players.

More companies in Regenerative Medicine →More companies in United States →